Therapy-related myelodysplastic syndrome-Acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: An emerging problem

Blood

Volumn 99, Issue 3, 2002, Pages 822-824

  Latagliata, Roberta ^a,b,c   Petti, Maria Concetta ^a,b   Fenu, Susanna ^a,b   Mancini, Marco ^a,b   Spiriti, Maria Antonietta Aloe ^a,b   Breccia, Massimo ^a,b   Brunetti, Gregorio A ^a,b   Avvisati, Giuseppe ^a,b   Coco, Francesco Lo ^a,b   Mandelli, Franco ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c Cattedra di Ematologia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL PROTOCOL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; LATENT PERIOD; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0036464656     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.3.822     Document Type: Article

References (34)

1. Acute promyelocytic leukemia: Biology and treatment
2. Current approaches to acute promyelocytic leukemia
3. Acute promyelocytic leukemia: A curable disease
4. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy: Gruppo Italiano-malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups
5. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine
6. All-trans retinoic acid in acute promyelocytic leukemia
7. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy
8. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: Result of the randomized MRC trial
9. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARa-positive acute promyelocytic leukemia
10. Differentiation therapy for acute promyelocytic leukemia with all-trans retinoid acid: 10-Year experience of its application
11. A randomized comparison of ATRA followed by chemotherapy and ATRA plus chemotherapy, and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia
12. Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: Effects in patients with newly diagnosed acute promyelocytic leukemia: German AML Cooperative Group
13. Increase therapy-related leukemia secondary to breast cancer
14. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor cell support for lymphoid malignancies
15. The incidence of secondary leukemia
16. A unique case of t(15;17) acute promyelocytic leukaemia (M3) developing into acute myeloblastic leukemia (M1) with t(7;21) at relapse
17. Translocation (3;21)(q26;q22) in treatment-related acute leukemia secondary to acute promyelocytic leukemia
18. Acute promyelocytic leukemia (M3): Relapse with acute myeloblastic leukemia (M2) and dic(5;17)(q11;p11)
19. Myelodysplastic syndrome following successful therapy of acute promyelocytic leukemia
20. Acute trilineage leukemia with monosomy of chromosome 7 following an acute promyelocytic leukemia
21. Therapy-related acute myeloid leukemia with a t(10;11)(q23;p15) following successful chemotherapy for acute promyelocytic leukemia with t(15;17)
22. Therapy-related acute myeloid leukemia after successful therapy for acute promyelocytic leukemia with t(15;17): A report of two cases and a review of the literature
23. A therapy-related myelodysplastic syndrome with unusual features in a patient treated for acute promyelocytic leukemia
24. Therapy-related myelodysplastic syndrome after eradication of acute promyelocytic leukemia: Cytogenetic and molecular features
25. Proposed revised criteria for the classification of acute myeloid leukemia: A report of the French-American-British cooperative group
26. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukemia
27. Identification of DNA rearrangements at the RARα locus in all patients with acute promyelocytic leukemia and mapping of APL breakpoints within the RARα second intron
28. Event-free survival (EFS) duration in newly diagnosed acute promyelocytic leucemia (APL) is favorably influenced by induction treatment with idarubicin alone: Final results of the GIMEMA randomized study LAP 0389 comparing IDA vs IDA + ARA-C in newly diagnosed APL
29. Proposals for the classification of the myelodysplastic syndromes
30. Therapy-related acute myelomonocytic leukemia following successful treatment for acute promyelocytic leukemia
31. Molecular remissions induced by liposomal-encapsulated alltrans retinoic acid in newly diagnosed acute promyetocylic leukemia
32. Therapy-related acute leukemia
33. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997
34. Definition of relapse risk and role of non anthracycline drugs for consolidation in patients with acute promyelocytic leukemia: A joint study of the PETHEMA and GIMEMA cooperative groups